Britain and America have announced a significant trade agreement that will preserve no levies on UK drug products being sold in the US market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to raise funding on pharmaceuticals through the NHS. This pledge secures that tariffs on these vital goods will stay at nothing for a timeframe of the next three years.
This deal follows earlier statements to dramatically increase duties on branded drug products, with potential rates discussed up to one hundred percent.
"This agreement between the Britain reinforces the global environment for new treatments and introduces much-needed equity to American-British medicine commerce," a statement noted.
Economic Importance
Pharmaceuticals are one of the Britain's most significant export categories to the America, which is clearly the largest destination for large companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months leading up to the third quarter, the UK shipped pharmaceutical products worth billions to the US. This value accounted for a significant portion of all goods exports in that period.
"This deal safeguards employment, stimulates funding and sets the stage for the UK to become a international leader for medical research," a government official stated.
Key British Pledges
The pact includes several key changes from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new medicines to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to double overall health service expenditure on treatments from 0.3% of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The sum drug companies must pay back to the NHS to prevent overspending will be restricted at fifteen percent. Last year, rebates were more than 20%.
Broader Context
The pact takes place against a protracted row between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
This friction were exacerbated by arguments that American customers were paying several times more for the equivalent treatments than patients in the UK and Europe.
In recent months, several major drug company projects in the UK have been halted or abandoned, while major investments have been pledged toward American operations.
A senior figure publicly accepted that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had decreased as a proportion of its total funding over the last ten years.
